Review Article

A Comprehensive Review on Unravelling the Complexity of Blood Cancer

Sayan Saha[1], Shreya Ghosh[2], Suman Ghosh[3], Sumit Nandi[4*]

[1]M. Pharm, Department of Biotechnology, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, West Bengal, India.
[2]M.Pharm, Department of Pharmaceutics, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, West Bengal, India.
[3]M.Pharm, Department of Pharmaceutical Chemistry, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, West Bengal, India.
[4]Assistant Professor, Department of Pharmacology, Gupta College of Technological Sciences, Asansol, West Bengal, India.
***Corresponding author's E-mail:** sumitrx27@gmail.com

Received: 12-01-2024; **Revised:** 23-02-2024; **Accepted:** 28-02-2024; **Published on:** 15-03-2024.

ABSTRACT

Blood cancer also referred to as haematological carcinoma, is a large category of malignancies that affects the bone marrow, lymphatic as well as blood systems. This comprehensive review highlights the current knowledge and understanding of blood cancer including general causes, risk factors, pathophysiology, general symptoms, diagnostic approaches, treatment modalities as well as future perspective of research. The paper begins by outlining the classification of blood cancers, highlighting the major subtypes such as lymphoma, luekemia as well as myeloma. It discusses the etiology as well as risk factors associated with these diseases, including genetic predispositions, exposure to certain environmental factors, and immune system dysregulation. A significant portion of the review focuses on the advancements in diagnostic techniques for blood cancers. It explores the role of various laboratory tests, imaging studies, and molecular profiling methods in establishing an accurate diagnosis, assessing disease prognosis, and guiding treatment decisions. Special emphasis is given to the emerging field of liquid biopsies, which hold promise for non-invasive monitoring and early detection of blood cancers. The review then delves into the diverse treatment options available for blood cancer patients. It provides an overview of medical therapies such as radiation therapy, chemotherapy as well as stem cell transplantation, while also discussing targeted therapies, immunotherapies, and novel therapeutic approaches currently under investigation. Furthermore, the paper highlights current developments in our comprehension of the genetic as well as molecular basis of blood cancers including identification of the key genetic mutations as well as aberrant signalling pathways. Lastly, the review discusses ongoing research efforts aimed at improving the diagnosis, treatment, and management of blood cancers. It sheds light on the development of novel therapeutics, immunotherapies, and adoptive cell therapies, as well as the potential applications of gene editing and gene therapy in blood cancer treatment.

Keywords: Blood cancer, Haematological carcinoma, Leukemia, Lymphoma, Myeloma, Immunotherapy, Chemotherapy.

INTRODUCTION

Cancer affecting the blood cells is called blood cancer. Blood cancer is mainly caused due to DNA modifications or mutations, in blood cells. These alterations are almost always connected to external factors.[1] Leukemia, also known as blood cancer, is a kind of blood or bone marrow cancer which is characterized by an irregular increase in immature white blood cells known as "blasts". It's a broad term that encompasses several illnesses that belong to a larger group of illnesses called hematological neoplasms, which affect the lymphatic, bone marrow, and blood systems.[2] Normal blood cells may eventually be displaced by blood cancer cells. Serious issues like anemia, bleeding, and infections may result from this. In addition to causing pain or swelling, blood cancer cells can spread to other organs or lymph nodes. Blood cancer can take several different forms.[3] Blood cells are produced in the bone marrow. Normally white blood cells are fight against infections. The body uses red blood cells to carry oxygen throughout it and platelets help in the blood clot[4.] Generally, in a blood cancer, unusually large quantities of white blood cells are produced by the bone marrow, known as blood cancer cells. They are not functional white blood cells. They proliferate more quickly than typical cells and never stop growing. Blood cancer cells have the potential to displace healthy blood over time.[5]

Survival rate in blood cancer statistical figures:

The survival rates for blood cancer vary depending on the particular type and stage of the disease, as well as individual factors like age, health, as well as response to treatment. It is necessary to remember that survival rates are statistical approximations and do not indicate a patient's specific course of treatment. Additionally, survival rates may change over time as new treatments and advancements in medical care are developed. Here are some general survival rate statistics for certain types of blood cancer. [6, 7]

TYPES OF BLOOD CANCER:

Blood cancers are a class of cancers that start in the bone marrow, where blood cells are produced. They are also referred to as hematological cancer malignancies. It is crucial to remember that there could be distinct subtypes or variations of every type of blood cancer and that the kind and stage of the disease could affect the available treatments. Blood cancer comes in a variety of forms, including:

1. Leukemia:

Leukemia is a type of malignancy which affects the blood as well as bone marrow is called leukemia. It is distinguished by the fast generation of aberrant white blood cells, which obstruct the normal blood cell-producing process. Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, as well as Chronic Myeloid Leukemia are four primary forms of leukemia.[8] Most prevalent form of leukemia in children is Acute Lymphoblastic Leukemia, whereas long-term Chronic Lymphocytic Leukemia is more prevalent in adults.[9] Leukemia is a kind of cancer originating from the bone marrow or blood and is defined by an abnormal increase in the production of blasts, or immature white blood cells. This is a complicated illness that can impair blood cells' ability to function normally as well as the body's capacity to fight infections, regulate bleeding, and carry oxygen. Leukemia is a general term that includes several subtypes, each with distinct traits and a different prognosis.[10] According to American Cancer Society Leukemia define as "Malignancy of the blood cells". Red blood cells are primary sources of bone marrow. Leukemia cells are aberrant white blood cells that produce bone marrow in large quantities when a person has leukemia. They proliferate more quickly than normal cells, perform functions not performed by common white blood cells, and cease growing when they ought to. Leukemia cells can eventually outnumber healthy blood cells, impairing their functionality".[11]

Table 1: Statistical figure of Survival rate in blood cancer

Types	Subtypes	Percentage
Acute Lymphoblastic Leukemia (ALL):	5-year survival rate for children	Approximately 90%
	5 years survival rate for adults	Approximately 40-50%
Acute Myeloid Leukemia (AML):	5 years survival rate for adults under 60	Approximately 50-60%
	5 years survival rate for adults over 60	Approximately 20-30%
Chronic Lymphocytic Leukemia (CLL)	5 years survival rate	Approximately 85-90%
	10 years survival rate	Approximately 75%
Chronic Myeloid Leukemia (CML)	5 years survival rate	Approximately 70-80%
	10 years survival rate	Approximately 60-70%
Hodgkin Lymphoma	5 years survival rate for early-stage (localized) disease	Approximately 90%
	5 years survival rate for advanced-stage (distant) disease	Approximately 80%
Non-Hodgkin Lymphoma	5 years survival rate varies widely depending on the specific subtype and stage of the disease, ranging	Approximately 60% to over 90%

1.1 General causes and Risk factors of Leukemia:

Specific causes of leukemia remain largely unknown. On the other hand, several potential risk factors for leukemia have been found. These are a few recognized causes, risk factors, and sources of leukemia.

A. Genetic factors: A higher chances of developing leukemia has been associated with specific genetic abnormalities, like chromosomal mutations as well as genetic syndromes. Li-Fraumeni syndrome, Down syndrome, and some hereditary bone marrow failure diseases are a few examples.[12]

B. Exposure to Ionizing radiation: Leukemia risk can be increased by high levels of ionizing radiation, like those received during nuclear accidents or some cancer treatments.[13]

C. Chemical exposures: Long-term exposure to some chemicals, like formaldehyde and benzene, has been connected to a higher risk of leukemia. These substances are employed in a few specific industries, including rubber manufacturing, petroleum refining, and some chemical production.[14]

D. Smoking: Smoking cigarettes has been associated with an increased risk of Acute lymphoblastic leukemia as well as Acute myeloid leukemia, especially in adults.[15]

1.2. Epidemiology:

The epidemiology of leukemia encompasses various aspects, including incidence rates, prevalence, mortality, and risk factors. Here is an overview of the epidemiology of leukemia, supported by multiple references:-

A. Incidence and prevalence: Leukemia represents approximately 3.6% of recently identified cases of cancer in the United States. Leukemia is thought to be responsible for 2.7% of cancer cases worldwide.[16]

B. Age and gender: Though the risk rises with age, leukemia may affect anyone at any age. Around 66 is the median age at which leukemia is diagnosed. There is a gender preference for certain types of leukemia. For example, men are more probably to have Chronic Lymphocytic Leukemia than women.[17]

C. Mortality: Leukemia is the cause of a considerable proportion of cancer-related deaths that occur globally. Leukemia is responsible for about 3.8% of all cancer related deaths in the US. The mortality rate for various leukemia subtypes varies and is affected by variables like age, subtype, and treatment response.[18]

1.3. Types of Leukemia:

Table 2: Types of Leukemia

Types of Leukemia	Description	Cause
Acute Lymphocytic Lymphoma (ALL)	Acute lymphoblastic leukemia (ALL) and Acute lymphocytic lymphoma (ALL) are related cancers that primarily affect lymphocytes[19] In Acute lymphocytic lymphoma, however, the cancer cells form large tumors in lymph nodes as well as other organs, while in Acute lymphocytic lymphoma, they mostly develop in the bone marrow and bloodstream.[20]	Malignant lymphoblasts build up as a result of the aberrant growth and proliferation of immature lymphocytes, typically B or T cells, which causes acute lymphocytic lymphoma. Tumor masses can be formed by these cancerous cells invading lymph nodes, the spleen, the thymus, and other organs. [20]
Acute Mylogenous Leukemia (AML)	Acute myeloid leukemia or Acute myelogenous leukemia, is a form of cancer affecting the myeloid cells in the bone marrow, which are responsible for the formation of platelets, RBC and WBC. Abnormal myeloid cells proliferate and accumulate uncontrollably in AML, interfering with the natural growth of normal blood cells.[21]	1. There are certain genetic abnormalities that can raise the risk of Acute mylogenous leukemia development. Gene mutations in FLT3, NPM1, and CEBPA are a few examples. 2. Extended exposure to specific chemicals, like benzene and some chemotherapy medicines has been linked to a higher chance of developing AML.[21]
Chronic Lymphotic Leukemia (CLL)	A form of cancer that affects lymphocytes which are a kind of white blood cell that is part of the immune system, is called chronic lymphocytic leukemia (CLL). The formation of mature and abnormal lymphocytes in the bone marrow, lymph nodes, blood, as well as other organs is an indication of Chronic lymphocytic leukemia.[22]	1. Genetic Factors: A higher chance of developing chronic lymphocytic leukemia has been linked to a number of inherited genetic conditions, including familial chronic lymphocytic leukemia and specific chromosomal abnormalities, such as the deletion of chromosome 13q. 2. Family History: The chance of getting chronic lymphocytic leukemia is increased if you have a parent or sibling who is a close family member. A younger diagnosis for the afflicted family member increases the risk.[22]
Chronic Mylogenous Leukemia(CML)	A form of cancer affecting the bone marrow as well as blood is called Chronic myelogenous leukemia. Excessive production of myeloid cells, or immature white blood cells, is what defines it.[23]	The movement of genetic material between chromosomes 9 and 22 causes an abnormality in genetics known as the Philadelphia chromosome, which is present in chronic mylogenous leukemia. The fusion gene BCR-ABL1 is created as a result of this translocation. Uncontrolled growth and division of myeloid cells are encouraged by an aberrant protein produced by the BCR-ABL1 gene.[23]
Hairy Cell Leukemia (HCL)	A chronic leukemia affecting the blood and bone marrow is called Hairy cell leukemia. characterized by an excessive buildup of hairy cells, or aberrant B lymphocytes, in the spleen, bone marrow as well as other organs.[24]	It's still unknown what exactly causes Hairy cell leukemia. However, a few risk factors have been linked to it, such as exposure to environmental agents and gene mutation.[24]

1.4. Pathophysiology:

Leukemia pathophysiology involves abnormal growth and accumulation of immature white blood cells (leukocytes) in the bone marrow as well as bloodstream. This includes various types of leukemia like Acute myelogenous leukemia, Acute lymphocytic leukemia, Chronic lymphocytic leukemia as well as Chronic myelogenous leukemia.[25]

A. Uncontrolled Cell Multiplication: Genetic alterations in blood cell DNA, especially in bone marrow stem cells which differentiate into various blood cell types, are the cause of leukemia. These mutations cause the regular control over cell growth to be disrupted, which results in the unchecked growth and accumulation of aberrant cells.[26]

B. Impaired Cell Differentiation: The genetic mutations causing leukemia hinder blood cells' ability to differentiate into fully functional cells. Blasts, or immature, undifferentiated cells, accumulate as a result of this. The capacity of bone marrow is to create healthy blood cells which are compromised by these blasts, which lack the typical features and functions of mature blood cells.[27]

C. Infiltration of Bone Marrow and Organs: As leukemia increases, the aberrant leukemic cells multiply and take the place of proper bone marrow cells. This results in a reduction in the generation of healthy blood cells, including mature red blood cells, white blood cells as well as platelets. Anemia as well as any elevated risk of infections can arise from this.[28]

D. Disruption of Normal Blood Cell Counts: The normal balance of various blood cell types is upset by the aberrant proliferation of leukemic cells. There is a sharp rise in blasts in acute leukemias (ALL and AML), which causes a drop in the quantity of healthy blood cells. Abnormal mature white blood cells also known as lymphocytes or myeloid cells, accumulate in chronic leukemias (CLL and CML) and block the normal cells in the bone marrow as well as bloodstream.[29]



Figure 1: Normal and Leukemia cells

E. Organomegaly and Tissue Infiltration: Organomegaly, or enlarged organs, can result from leukemia cells infiltrating and accumulating in multiple organs, including the liver, spleen, lymph nodes as well as CNS. This can also impair the organs' normal function. This may result in symptoms like weariness, enlarged lymph nodes, and discomfort in the abdomen.[30]

Each type of leukemia can have different genetic mutations and specific pathophysiological mechanisms, which can affect how the disease progresses, how it looks clinically, and how well it responds to treatment.

1.5. General signs and symptoms:

Depending on the stage and nature of the disease, leukemia can exhibit a wide range of signs and symptoms. Here are a few general leukemia-related signs and symptoms, along with a recommended reading list.

A. Fatigue and Weakness: Leukemia frequently manifests as persistent fatigue, weakness, as well as a generalized sense of exhaustion. This weariness may be exacerbated by the malignant cells along with their effects on normal blood cells.[31]

B. Fever and Night Sweats: Leukemia may be the cause of unexplained, recurrent fevers that are frequently accompanied by night sweats. The reaction of immune system to the cancer cells may be the cause of these symptoms.[32]

C. Frequently Infections: People with leukemia may have weakened immune systems, which increases their susceptibility to infections. Leukemia may manifest as recurrent or persistent infections, like urinary tract or respiratory infections.[33]

D. Bleeding and easy bruising: Leukemia can interfere with platelet production, which makes bleeding and bruising easier. People may experience prolonged bleeding from small wounds or injuries, bleeding gums, or frequent nosebleeds.[33]

E. Enlargement of Spleen, Lymph Nodes or Liver: In certain leukemia cases, the malignant cells may result in the enlargement of the spleen, lymph nodes or liver. Certain body parts may swell or develop lumps as a result of this enlargement.[34]

It's important to remember that these are general indications and symptoms, and leukemia cases can manifest in various ways. Some people may start with few or no symptoms. For an accurate assessment and diagnosis, it's crucial to speak with a healthcare provider if you have any serious symptoms or specific health concerns.

1.6. Diagnosis of Leukemia:

Leukemia is diagnosed by the various laboratory testing, physical testing, review of medical history as well as occasionally bone marrow testing. Here are some diagnostic processes for leukemia:

A. Medical history and physical testing: A physician will obtain a thorough medical history that includes the patient's symptoms, duration, and any pertinent family history or risk factors. In order to evaluate symptoms like enlarged lymph nodes, enlarged organs, or unusual bleeding or bruising, a physical examination is going to be conducted.

B. Blood tests: Leukemia diagnosis depends heavily on blood tests. A complete blood count (CBC) is used to determine the quantity and variety of blood cells in the body. Leukemia may be suspected in cases of abnormal results such as low level of platelets (thrombocytopenia), red blood cells (anemia), and high level or low level of white blood cells. Blood chemistry panels to assess organ function and particular markers or genetic tests that detect specific types of leukemia are examples of additional tests that may be performed.[35]

C. Bone marrow examination: To determine the diagnosis and identify the specific type of leukemia, an aspiration of bone marrow and biopsy are frequently carried out. During this process, a needle is used to remove a small sample of bone marrow as well as a core of bone, typically from the hip bone. The samples are inspected under a microscope to determine whether any aberrant cells are present and what kind of cells they are.[36]

D. Cytogenetic and Molecular Testing: To find particular genetic abnormalities linked to various forms of leukemia, bone marrow or blood samples are frequently subjected to cytogenetic analysis and molecular testing. The results of these tests inform treatment choices and help establish prognosis.[37]

E. Imaging studies: To determine the degree of disease involvement and spot any organ enlargement or

abnormalities in the lymph nodes, imaging studies such as X-rays, ultrasounds, CT scans or Positron Emission Tomography (PET) scans may be carried out.

F. Lumbar Puncture (Spinal Tap): In certain leukemia cases, a lumbar puncture may be carried out to determine whether malignant cells have spread to the CNS and cerebrospinal fluid (CSF).[38]

1.7. Treatment of Leukemia:

The types of leukemia, age of the patient, health as well as certain genetic or molecular traits are some of the variables that affect how the disease is treated. Chemotherapy, immunotherapy, radiation therapy, targeted therapy as well as stem cell transplantation may be used as leukemia treatment options. Here are some common leukemia treatment approaches and a link to additional resources, those are as follows:

A. Chemotherapy: Using medications to either kill or control cancer cells, chemotherapy is a common treatment of leukemia. It can be injected intravenously, orally, or straight into the Cerebrospinal fluid. Depending on the types of leukemia and patient's condition, different chemotherapy drug combinations and schedules are used.[39]

B. Targeted therapy: Targeted therapy aims to stop the growth and survival of cancer cells by concentrating on particular molecular or genetic abnormalities. Targeted therapies, such as monoclonal antibodies or tyrosine kinase inhibitors, can be used to minimize harm to healthy cells while specifically targeting cancer cells in certain types of leukemia.[40]

C. Radiation therapy: To inhibit the growth of leukemia cells, high-energy radiation is used in radiation therapy. It is often utilized in confined regions, like the brain or spleen, or in conjunction with stem cell transplantation. The two primary methods for treating leukemia are internal radiation therapy (brachytherapy) and external radiation therapy.[40]

D. Immunotherapy: Immunotherapy enhances the ability of the immune system to identify and remove the cancerous cells. It consists of CAR-T cell therapy as well as monoclonal antibodies. By altering the T cells of a patient CAR-T cell therapy enables the T cells of the patients to identify and eliminate leukemia cells.[41]

E. Stem Cell Transplantation or Bone marrow transplantation: Stem cell transplantation is the process of substituting healthy stem cells for bone marrow that has been destroyed or damaged. For some leukemia patients, particularly those with high-risk disease or those who have relapsed after the first treatment, this procedure may be an option.[42]

2. Lymphoma:

One kind of malignancy affecting the immune system's lymphatic system is called lymphoma. The unusual growth of cells in the spleen, lymph nodes or other lymphatic tissues is indicating the presence of Lymphoma.[43]

2.1 General causes of lymphoma:

Most of the time, the precise cause of lymphoma is still unknown. Nonetheless, scientists have discovered a number of different factors that can raise the likelihood of getting it, which can be broadly divided into:

A. Genetic mutations: Lymphoma, like the majority of malignancies, is caused by genetic alterations (mutations) in lymphocytes, which are white blood cells. These mutations cause these cells to proliferate uncontrollably and develop tumors by interfering with their regular cycle of development and death. Age and family history are two variables that may contribute to these changes, even if the precise cause is frequently unknown.[44]

B. Weakened immune system: A weakened immune system leaves you more susceptible to developing lymphoma. This may be brought on by illnesses like HIV/AIDS, autoimmune disorders, or drugs that weaken the immune system following organ transplantation.

C. Viral infections: A higher risk of developing some types of lymphomas has been associated with certain viruses, including the Hepatitis C virus, Human T-cell Leukemia Virus (HTLV-1), and Epstein-Barr virus (EBV).[45]

D. Chemical and Radiation exposure: Prolonged exposure to some chemicals, such as herbicides and benzene, which are employed in several sectors, has been connected to a higher risk of certain lymphomas. And it also having received high doses of radiation for cancer treatment in the past increases the chance of developing lymphoma in the future.[46]

2.2 Risk factors:

Several factors are identified that may increase the risk of developing the disease. There are some key points for risk factors of lymphoma:

A. Immune system deficiencies: Peoples with weakened immune systems are more vulnerable to lymphoma. This comprises individuals who have congenital immune weaknesses, have received organ transplants, are on immunosuppressive medications, or have HIV/AIDS.[47]

B. Infections: A higher incidence of lymphoma has been linked to specific bacterial and viral infections. As an illustration, adult T-cell lymphoma is related to the Human T-cell lymphotropic virus (HTLV-1), whereas Hodgkin lymphoma and certain kinds of NHL are linked to the Epstein Barr Virus (EBV).[48]

C. Family history: Having a close relative who has lymphoma may raise the chances of getting the disease, especially if they are a first-degree relative (parent or sibling). This implies a potential hereditary susceptibility to lymphoma, while the precise genetic components remain incompletely determined.

D. Gender: Certain lymphoma subtypes are more common in one gender than the other. For instance, although some Non-Hodgkin lymphoma likes primary B-cell lymphoma are more commonly diagnosed in women. Hodgkin lymphoma is slightly more common in men.[49]

E. Obesity: Research indicates that obesity may be connected with a greater incidence of lymphomas including follicular as well as diffuse large B-cell lymphomas (DLBCL). It's unclear exactly what mechanisms underlie this relationship.[49]

2.3 Types of lymphoma:

Lymphoma is a form of cancer that affecting the lymphatic system which is a part of the immune system in the body. Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) are the two primary forms of lymphoma. These two primary forms of lymphoma further subdivided into five categories each. Let's review all of these categories in greater depth:

A. Hodgkin lymphoma (HL): Big and abnormal cells that are present in lymph nodes like Reed-Sternberg cells, indicating the Hodgkin lymphoma. Both older persons ages of over 50 and young adults in between 20 to 40 years are frequently affected.[50]

Table 3: Types of Lymphoma





Figure 2: Types of Hodgkin Lymphoma

There are various subtypes of Hodgkin Lymphoma those are as follows:[51]

- **Nodular Sclerosis Hodgkin Lymphoma (NSHL):** This subtype makes up roughly 70% of all cases of HL and is the most prevalent. Young adults are usually affected, and the condition usually manifests as enlarged lymph nodes, especially in the chest region.
- **Mixed Cellularity Hodgkin lymphoma (MCHL):** this subtype is more prevalent in elderly individuals and is distinguished by the presence of immune cells other than Reed-Sternberg cells.
- **Lymphocyte Rich Hodgkin Lymphoma (LRHL):** This rare subtype is distinguished by a high proportion of lymphocytes, a particular kind of white blood cell, and a low number of Reed-Sternberg cells.
- **Lymphocyte Depleted Hodgkin Lymphoma (LDHL):** It is the very much least common subtype; it is marked by a high concentration of Reed-Sternberg cells and a dearth of lymphocytes. It frequently occurs in immune system-compromised individuals.
- **Nodular Lymphocyte Predominant Hodgkin lymphoma:** Popcorn cells or lymphocyte predominant cells are the distinguishing feature. Compared to the usual Reed-Sternberg cells seen in this type of Hodgkin lymphoma, these cells are distinct.

B. Non-Hodgkin lymphoma (NHL): It is a type of lymphoma where the Reed-Sternberg cells are not present. It can happen at any age, though the risk rises with age, and is more prevalent than HL.[52]

There are various subclasses of Non-Hodgkin lymphoma, those are categorized according to their growth pattern, other features, and whether B or T cells are the lymphocytes involved.[53]

- **Diffuse Large B-cell lymphoma:** This subtype observes in approximately all around 30% of the cases, it is the most prevalent kind of NHL. It usually manifests as quickly expanding lymph nodes and can affect any part of the body.
- **Follicular lymphoma:** This subtype is distinguished by aberrant B cell proliferation in a configuration similar to that of a normal lymph node. Usually slow-growing and indolent, it is diagnosed at a stage of progression.
- **Mantle cell lymphoma:** This subtype of lymphoma is distinguished by an excessive growth of B cells within

the mantle zone of lymph nodes. It usually affects older adults, and a more advanced stage of diagnosis is frequently obtained.

- **Burkitt lymphoma:** Mostly affecting children and young adults, this is an uncommon subtype of Non-Hodgkin lymphoma. It usually affects the jaw, abdomen, or other extra nodal sites and is linked to a particular genetic abnormality.
- **Peripheral T-cell lymphoma:** A variety of lymphomas involving T cells fall under this category. Anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma as well as peripheral T-cell lymphoma are few of the subtypes.

2.4 pathophysiology:

There are some underlying pathophysiological mechanisms shared by both types of lymphomas. Now let us examine them more thoroughly:

A. Genetic changes: A major part of the pathophysiology of lymphoma is genetic alteration. The normal control of cell division, survival, and differentiation can be scared by chromosomal translocations, mutations, and gene amplifications, which can result in the advancement of lymphoma. For instance, chromosomal abnormalities involving the 9p24.1 region are frequently seen in Reed-Sternberg cells in Hodgkin lymphoma. These abnormalities result in overexpression of the genes for Programmed Death Ligand 1 and Programmed Death Ligand 2; those are aid the tumour in evading immune responses.[54]

B. Dysregulation of cell signalling pathways: Immune system alterations may play a role in lymphoma development. The risk of developing certain types of lymphoma is increased by immune deficiencies, such as congenital immunodeficiencies or HIV infection. Furthermore, long-term inflammation and persistent antigenic stimulation can cause genetic changes and encourage the development of lymphomas.[55]

C. Immune dysregulation: Immune surveillance and response rely heavily on the lymphatic system. A dysregulated immune system plays an important role in the development of lymphoma. For example, Hodgkin and Reed-Sternberg cells and the surrounding immune cells interact dysregulated in Hodgkin Lymphoma. Through a variety of strategies, including modified expression of immune checkpoint molecules, Hodgkin and Reed-Sternberg cells avoid immune surveillance. Immune dysfunction in NHL may be linked to immunosuppression, infection, or chronic inflammation, all of which promote the growth of lymphoma cells.[56]

D. Tumour microenvironment: The extracellular matrix, cytokines, and a complex network of cells interact with lymphoma cells in the tumour microenvironment. Within the microenvironment, stromal cells, immune cells, and endothelial cells are involved in tumour growth, angiogenesis, and metastasis. The Non-Hodgkin Lymphoma microenvironment is critical to the course of the disease and how well it responds to therapy. For instance, an abundant microenvironment full of immune cells and cytokines, which support lymphoma cell growth and survival, is a characteristic of follicular lymphoma.[57]

E. Epigenetic changes: Histone modifications and DNA methylation are the examples of epigenetic changes that can affect gene expression patterns and helps in the development of lymphomas. Lymphoma patients exhibit aberrant DNA methylation patterns, which may impact the expression of oncogenes or tumour suppressor genes. Aside from influencing gene expression, histone modifications like acetylation and methylation can also aid in the development of lymphomas.[58]

2.5 Signs and symptoms of lymphoma:

The type, stage, and location of the cancer can affect the signs and symptoms of lymphoma. It is noteworthy that there are other non-cancerous conditions that can also be linked to these symptoms.

A. Enlarged lymph nodes: Lymph nodes, which can feel like painless lumps under the skin, are one of the most obvious indicators of lymphoma. Often affected lymph nodes are those in armpits, and neck.[59]

B. Weight loss: Less than 15% of body weight lost in six months, which is commonly referred to as significant and unexplained weight loss, may indicate lymphoma.

C. Chest pain and breathing difficulties: Lymphoma can sometimes affect the mediastinum, or space between the lungs, resulting in symptoms like coughing, breathing problems, facial or neck swelling, and chest pain.[60]

D. Sweating, fatigue and fever: Profuse sweating particularly at night, Persistent fatigue, weakness, and persistent or recurrent fever without an apparent cause can be a symptom of lymphoma.

2.6 Diagnosis of lymphoma:

A combination of clinical assessment, imaging studies, laboratory testing, and occasionally a biopsy to look at affected tissues are used to diagnose lymphoma. The following are the standard techniques for diagnosing lymphoma:

A. Physical examination and medical history: It is important to obtain thorough a medical history in order to comprehend the symptoms of patients, underlying diseases, and risk factors. A comprehensive physical examination will be conducted, which will involve palpating lymph nodes and looking for additional lymphoma symptoms.

B. Blood tests: Blood tests are carried out to assess the patient's general health and search for particular markers linked to lymphoma. A complete blood count (CBC) and tests regarding blood chemistry panel to evaluate kidney and liver function are a few examples of these tests. Furthermore, certain indicators like beta-2 microglobulin

levels and lactate dehydrogenase (LDH) can reveal more details about the illness.[61]

C. Imaging tests: To stage lymphoma and assess the disease's progression, imaging methods are essential. Those are: Computed Tomography (CT) scan, X-rays, Positron Emission Tomography (PET) scan, Magnetic Resonance Imaging (MRI).[62]

D. Biopsy: The general method for diagnosing lymphoma is a biopsy. A tiny sample of tissue from an affected lymph node or other affected areas must be removed, and it must then be examined under a microscope. The biopsy can be carried out in a number of ways, such as: Excisional biopsy, Fine-needle aspiration (FNA) biopsy, Incisional biopsy, Core needle biopsy.[63] The biopsy sample is sent to a pathologist who examines the cells to determine the type of lymphoma and its characteristics. This information helps guide treatment decisions.

2.7 Treatments of lymphoma:

General health of the patient's, stages of illness and their treatment preferences are just a few of the variables that affect how lymphoma is treated. Combinations of treatments, such as chemotherapy, radiation therapy, immunotherapy, targeted therapy as well as stem cell transplantation, are frequently used to treat lymphoma. Here are a few lymphoma treatments that are frequently used:

A. Chemotherapy: This treatment uses medicines to kill maximum cancers cells. It can be taken orally or intravenously, either on its own or in conjunction with other therapies. Different lymphoma types and stages are treated with different chemotherapy regimens. Vincristine, prednisone, doxorubicin, and cyclophosphamide are a few examples of chemotherapy medications that are frequently used.[64]

B. Radiation therapy: Targeting and eliminating cancer cells with high-energy beams is the goal of radiation therapy. It is frequently used to treat particular disease-affected areas or localized lymphomas. External and internal beam radiations are two ways that radiation therapy can be administered.[65]

C. Immunotherapy: Immunotherapy uses the body's defenses against cancer to identify and eliminate cancerous cells. For the treatment of lymphoma, monoclonal antibodies like rituximab, obinutuzumab, and brentuximab vedotin are frequently utilised. They can strengthen the immune system's defences against cancer cells or specifically target cancer cells.[66]

D. Targeted therapy: By interfering with particular molecules necessary for cancer cells to grow and survive, targeted therapy medications are intended to specifically target and inhibit the growth of cancer cells. For instance, targeted medications like venetoclax, idelalisib, or ibrutinib may be used to treat specific forms of lymphoma that have genetic alterations.[67]

E. Stem cell transplantation: It is an option for certain lymphoma cases, especially high-risk or relapsed/refractory cases. It entails swapping out unhealthy stem cells for healthy ones. Allogeneic transplantation uses stem cells from a matched donor, autologous transplantation uses the patient's stem cells. It is significant to remember that different treatment modalities can be used based on the specific subtype and type of lymphoma (Non-Hodgkin or Hodgkin). Decisions about a patient's course of treatment are also heavily influenced by personal characteristics and preferences.[68]

3. Multiple Myeloma:

It is a kind of cancer that affects plasma cells, a subset of white blood cells that are involved in the immune response. Uncontrollably multiplying abnormal plasma cells in the bone marrow produce abnormal proteins and excrete out healthy blood cells, which is how myeloma develops. All around 1% of cancers and 10% of all hematologic malignancies in western countries. Multiple myeloma is the second most common hematologic cancer. With a median diagnosis age of approximately 69 years, it primarily affects older adults. In Multiple myeloma's precise cause is unknown, however there are various risk factors that have been found like advanced age, male gender, african-american ethnicity, radiation or chemical exposure, a family history of the disease and specific pre-existing conditions like solitary plasmacytoma and Monoclonal Gammopathy of Unknown Significance (MGUS).[69]

3.1 Types of Myelomas:

With numerous subtypes and classifications, multiple myeloma is a complicated illness. Multiple myeloma classification schemes have developed over time; the most recent scheme is based on the disease's genetic and molecular features. The following are some significant myeloma types:

A. Immunoglobulin Subtype: Sorting multiple myeloma according to the kind of immunoglobulin the aberrant plasma cells produce is possible. The most prevalent subtypes are as follows: [70]

- **IgG Myeloma:** It produces aberrant IgG immunoglobulins and makes up about 50% of cases of multiple myeloma.
- **IgA Myeloma:** This disease, which makes up 20% of cases, is distinguished by the aberrant production of IgA immunoglobulins.
- **Light chain Myeloma:** Only the light chains of immunoglobulins either lambda (λ) or kappa (κ), are produced by aberrant plasma cells in this subtype. Kappa light chain myeloma and lambda light chain myeloma are the two additional subtypes of light chain myeloma.

B. Non-secretory Myeloma: This uncommon subtype of myeloma is distinguished by the lack of measurable monoclonal proteins in the urine or blood. This subtype's

diagnosis and follow-up are dependent on additional markers, like aberrant bone marrow plasma cell counts or imaging analyses.[71]

C. Solitary Plasmacytoma: It usually found in soft tissue or bone, solitary plasmacytoma is the existence of a single tumour made of plasma cells. Depending on where the tumour is located, it can be further divided into solitary bone plasmacytoma and solitary extramedullary plasmacytoma. It is significant to remember that as our knowledge of the illness advances, the classification and subtyping of myeloma may change further. Prognosis and treatment choices may also be influenced by molecular abnormalities and unique patient characteristics.[72]

3.2 Causes of Myeloma:

Although the precise causes of multiple myeloma remain unclear, a number of factors have been found to potentially play a role in the illness's progression. The following are some recognised myeloma risk factors and possible causes:

A. Genetic Predisposition: Multiple myeloma may be influenced by genetic factors, according to available data. An elevated risk of myeloma has been linked to certain genetic abnormalities, including chromosomal translocations involving the Immunoglobulin Heavy chain gene (IGH) and oncogenes like c-MYC.[73]

B. Gender and Age: Multiple myeloma can occur most of the people over 65 years and the risk of developing the disease rises with the age. A higher risk of multiple myeloma following Monoclonal Gammopathy of Unknown Significance (MGUS) is present in American veterans who are White and African American. Multiple myeloma is slightly common in men than women.[74]

C. Monoclonal Gammopathy of Undetermined Significance (MGUS): It is a condition in which the presence of abnormal protein levels in the blood (monoclonal protein, or M-protein), but no other myeloma symptoms or signs. MGUS is thought to be a prelude to myeloma, and over time, those who have MGUS are more likely to develop myeloma.[75]

D. Environmental Exposures: Research has indicated a possible connection between specific environmental or occupational exposures and the onset of myeloma. For instance, myeloma risk may rise with exposure to specific chemicals like benzene and pesticides.[76]

3.3 Death and survival rate of Multiple Myeloma:

Table 3: Statistical data of Multiple Myeloma patient characteristics and incidence patterns

		Blacks		Whites		
		n %	Incidence	n %	Incidence	Ratio
Sex	Male	2883 (50)	13.2 (12.7-13.7)	15 255 (53)	6.1 (6.0-6.2)	2.16
	Female	2915 (50)	9.6 (9.2-9.9)	13 684 (47)	4.0 (3.9-4.1)	2.40
	Total	5798 (100)	11.0 (10.7-11.3)	28 939 (100)	4.9 (4.8-4.9)	2.25
Year of Multiple Myeloma diagnosis	1973-1979	744 (13)	10.1 (9.3-10.9)	4536 (15)	4.5 (4.4-4.6)	2.24
	1980-1986	1048 (18)	10.9 (10.3-11.7)	5424 (19)	4.7 (4.6-4.8)	2.32
	1987-1993	1244 (21)	11.2 (10.5-11.8)	6384 (22)	5.0 (4.9-5.1)	2.24
	1994-1998	1097 (19)	11.9 (11.2-12.7)	5074 (18)	5.1 (5.0-5.3)	2.33
	1999-2005	1665 (29)	11.0 (10.5-11.6)	7521 (26)	5.0 (4.9-5.1)	2.20
Age	< 50	633 (11)	1.2 (1.1-1.3)	1629 (5)	0.4 (0.4-0.4)	3.00
	50-69	2787 (48)	24.0 (23.1-24.8)	11 490 (40)	9.7 (9.5-9.9)	2.47
	≥ 70	2378 (41)	62.2 (59.7-64.7)	15 820 (55)	30.4 (29.9-30.8)	2.05

3.4. Pathophysiology:

Multiple myeloma is essential to comprehend the disease's underlying pathophysiology in order to create efficient treatment plans and enhance patient outcomes. This paper explores the impact of Multiple Myeloma on different bodily systems by delving into the complex mechanisms and processes associated with the condition.

A. Initiating Events and Progression: Although the precise cause of MM is still unknown, several factors are thought to be involved. Those are:

- **Genetic abnormalities:** Uncontrolled growth of plasma cells is related to mutations in genes such as TP53, NRAS, and MYD88.
- **Epigenetic modifications:** Oncogenes can be activated and tumor suppressor genes silenced by variations in histone modifications and DNA methylation.
- **Microenvironment interactions:** The signals that the bone marrow microenvironment produces help myeloma cells proliferate and endure.[77]

B. Pathophysiological Mechanisms:

- **Production of M-proteins:** Abnormal copies of normal antibodies, known as monoclonal proteins are produced by myeloma cells.
- **Suppression of normal hematopoiesis:** Anemia, neutropenia, and thrombocytopenia are caused by myeloma cells crowding out healthy blood cell-producing cells in the bone marrow.
- **Immune dysfunction:** People with myeloma may have compromised immune systems, which increases their susceptibility to infections.[78]

C. Effect on Various Systems:

- **Skeletal system:** One of MM's hallmarks is bone destruction, which can cause pain, fractures, and hypercalcemia.
- **Hematopoietic system:** Fatigue, an elevated risk of infection, and bleeding issues can result from anemia, neutropenia, and thrombocytopenia.
- **Renal system:** Kidney failure can result from kidney damage caused by M-protein deposition.
- **Nervous system:** Rarely, MM may have an impact on the nervous system, leading to symptoms such as weakness, tingling, and numbness.[79]

3.5. Signs and symptoms of myeloma:

Multiple myeloma can present with a variety of signs and symptoms, which can vary among individuals. Here are some common signs and symptoms of myeloma with a reference

A. Bone Pain: Bone pain is one of the most common symptoms, especially in the back, ribs, hips, and skull. Many people describe the pain as a dull, ongoing ache. When you move or apply pressure to the affected area, it might get worse.[80]

B. Anemia: Low red blood cell count is a common symptom of anaemia, which is commonly associated with myeloma. Weakness, exhaustion, pale skin, and shortness of breath are possible side effects.[81]

C. Kidney Issues: Myeloma can impact the kidneys, resulting in a range of kidney-related symptoms, including heightened thirst, frequent urination, frothy urine, lower limb edema, and abnormalities in electrolytes.[82]

D. Hypocalcaemia: Elevated blood calcium levels, can be a symptom of myeloma and cause symptoms like increased thirst, dehydration, disorientation, constipation, and increased urination.

These are but a few of the typical myeloma symptoms and indicators. It is crucial to remember that different people with myeloma may have different symptom combinations, and some people may not have any symptoms at all when their condition is diagnosed.

3.6 Diagnosis of Myeloma:

A combination of clinical assessment, laboratory testing, imaging studies, and bone marrow examination is usually used to diagnose multiple myeloma. The following are typical methods for diagnosing myeloma, along with a source:

A. Medical History and Physical Examination: The physician will check the medical history of the patient, taking note of any myeloma-related symptoms or risk factors. One way to check for myeloma symptoms, such as organomegaly (enlarged organs) or bone tenderness, is to do a physical examination.

B. Blood and Urine Tests: Myeloma is diagnosed through a number of laboratory tests. Among them are:

- **Blood tests:** Anemia and abnormally high or low levels of various blood cell types can be found with a complete blood count (CBC). Immunofixation electrophoresis (IFE) and serum protein electrophoresis (SPEP) are methods used to identify aberrant proteins in blood, such as free light chains or monoclonal (M) proteins. Tests for blood chemistry evaluate calcium levels, kidney function, and other metabolic factors.
- **Urine tests:** To determine the presence of aberrant proteins, especially Bence Jones proteins, a light chain of immunoglobulin, a 24-hour urine collection is carried out.[83]

C. Imaging Studies: A variety of imaging methods are useful in assessing bone loss and determining the severity of the illness. These may include:

- **X-rays:** Bone lesions, fractures, and other anomalies connected to myeloma are frequently evaluated using skeletal survey X-rays.
- **Magnetic Resonance Imaging (MRI):** It is very sensitive to identifying spinal cord compression and bone marrow involvement.
- **Computed Tomography (CT) Scan:** To evaluate organs, lymph nodes, and possible extramedullary involvement, CT scans can provide details of the chest, abdomen, and pelvis.[84]

D. Bone Marrow Examination: Bone marrow biopsy and aspiration are mandatory to diagnose myeloma. These operations entail taking bone marrow samples from the hipbone or other locations in order to conduct cytogenetic analysis and Fluorescence in Situ Hybridization (FISH) as well as other tests to determine whether aberrant plasma cells are present.[85]

It's crucial to remember that the diagnostic procedure may change based on specific patient characteristics and recommendations for clinical practice.

3.7. Treatment of Myeloma:

The course of treatment for multiple myeloma is determined by a number of variables, such as the patient's general health, stage of diseases as well as the unique features of the myeloma cells. For myeloma, treatment strategies usually include a mix of treatments. The following list of frequently used for myeloma treatments:

A. Chemotherapy: To eradicate cancer cells or stop their growth, chemotherapy medications are frequently used to treat myeloma. Combinations of medications such as bortezomib, lenalidomide, and dexamethasone are frequently used in chemotherapy regimens.[86]

B. Stem Cell Transplantation: A high dose of chemotherapy is typically followed by Autologous Stem Cell Transplantation (ASCT). Before receiving high-dose chemotherapy, an ASCT patient's own healthy blood-forming stem cells are extracted, and the stem cells are injected back into the patient's body to restart the production of blood cells.[87]

C. Targeted Therapies: The purpose of these therapies is to obstruct particular molecular pathways that are essential to myeloma cell growth and survival. Targeted therapies for myeloma treatment include immunomodulatory medications like thalidomide and proteasome inhibitors like carfilzomib.

D. Immunotherapy: Immunotherapy approaches, such as monoclonal antibodies, have shown encouraging results in the treatment of myeloma. Antibodies such as Daratumumab and Elotuzumab binds some specific target proteins on myeloma cells, helping to acknowledge the immune system and eliminate the myeloma cells.[88]

4. Myelodysplastic syndromes (MDS):

The World Health Organization 2008 classification places the diverse group of hematopoietic stem cell disorders known as Myelodysplastic syndromes (MDS) under the category of chronic myeloid malignancies.[89] The occurrence of Myelodysplastic syndromes in the United States is roughly 3.4 cases per 1 lakh people annually, and it rises with age, with patients over 70 years old experiencing about 30 cases per 1 lakh people annually. Although bone marrow is hypercellular or normal, Myelodysplastic syndromes is diagnosed by peripheral blood cytopenias, primarily due to inefficient marrow hematopoiesis. Because of this, peripheral blood cytopenia-related complications are common in the clinical course of Myelodysplastic syndromes patients, and 30% of them also have an inherent risk of leukemic transformation. Patients with Myelodysplastic syndromes have wildly varying outcomes; the median survival time is less than six months and can be over five years. In order to accurately stratify these patients' risks, several prognostic scoring methods have been established over time.[90,91,92] In addition, we now have a better understanding of the molecular pathophysiology of this illness thanks to the recent identification of frequently mutated genes related to signalling, chromatin modification, spliceosomal machinery, epigenetic regulation, as well as DNA repair pathways.[93,94,95] Furthermore, these genetic abnormalities are being used as novel therapeutic targets for recent clinical trials in Myelodysplastic syndromes and as a means of improving our current diagnostic and prognostic methodology. There are currently just three FDA-approved medications for the treatment of Myelodysplastic syndromes, and none of them are curative. With an age of 70 to 75 years, Allogeneic Stem Cell Transplantation (ASCT) is the only therapeutic intervention however the morbidity and death rate associated with ASCT make it impractical for the vast majority of Myelodysplastic syndromes patients.[96,97] In order to provide specific recommendations for therapy for Myelodysplastic syndromes, due to the diseases highly heterogeneous clinical course and the lack of curative pharmacological therapies, careful consideration of patient and disease features must be made.

5. Myeloproliferative neoplasms (MPN):

The committee of World Health Organization for hematopoietic tumor classification was called to Chicago, Illinois at the beginning of 2014, with the intention of amending its 2008 document, which included the classification of chronic myeloid neoplasms.[98] Essential thrombocythemia (ET), Polycythemia vera (PV), as well as Primary myelofibrosis (PMF) are examples of BCR-ABL1-negative myeloproliferative neoplasms (MPNs). A premeeting suggestion from influential committee members emphasized the significance of the role of bone marrow morphology in Essential thrombocythemia diagnosis, particularly in differentiating it from “Prefibrotic Primary Myelofibrosis” and “Masked Polycythemia Vera”. For the latter, the characteristics are as follows: hemoglobin concentrations below the threshold levels of 19.5 g/dL in men and 15.5 g/dL in women, that convert to g/L, multiply by 10 and bone marrow structure consistent with Primary myelofibrosis and Polycythemia vera but without overt fibrosis (Prefibrotic primary myelofibrosis).[99] The specific proposal also emphasized the growing significance of novel mutations in disease prognosis and diagnosis, such as the recently identified Calreticulin (CALR) mutation. The identification of novel mutations in MPN has additionally aided in the advancement of therapeutic approaches that target specific molecules, such as inhibitors of Janus kinase (JAK), which demonstrate the potential in managing constitutional symptoms and splenomegaly in patients with MF6 or Polycythemia vera.[100,101]

6. Waldenstrom macroglobulinemia:

Immunoglobulin monoclonal proteins (IgM) as well as Lymphoplasmacytic bone marrow infiltration are two types of characteristic features of Waldenstrom macroglobulinemia (WM), which is a unique hematologic malignancy. A significant percentage of patients are asymptomatic when they are diagnosed, and most often present at an advanced age.[102] Hematologists may fail to recognize a unifying diagnosis of Waldenstrom Macroglobulinemia in symptomatic patients due to the

wide range of non-specific symptoms. While symptoms related to neuropathy and constitutional conditions are the most common, concurrent IgM-induced hyper viscosity-associated features can offer helpful diagnostic hints.[103] There are signs that therapy should be started. In addition to stressing the most recent findings of (Myeloid differentiation primary response 88) MYD88 as well as (C-X-C chemokine receptor type 4) CXCR4 mutations, which have provided previously unheard of insight into the intricate signaling pathways and created opportunities for novel therapeutic targeting, this review concentrates on the most recent management approaches for Waldenstrom Macroglobulinemia.[104] Despite the fact that WM is still incurable, its clinical trajectory seems to be improving in the future due to the quick development, application of innovative as well as effective treatments.

7. PREVENTION OF BLOOD CANCER:

Preventing blood cancer, including myeloma, is challenging because the exact causes are not well understood. However, there are some general strategies that can potentially reduce the risk of developing blood cancer. Here are some preventive measures that may help, along with a reference:

A. Healthy Lifestyle Options: Living a healthy lifestyle can help lower the risk of blood cancer as well as other cancers. This includes:

- **Avoiding Tobacco:** Reducing the use of tobacco products, including smokeless tobacco and cigarettes, can help reduce your chance of blood cancer. There is evidence connecting smoking to a higher risk of some blood cancers, including acute myeloid leukemia (AML).
- **Balanced Diet:** Balancing diet in fruits, vegetables, whole grains and proteins can lower the risk of cancer and help keep the immune system strong. Reducing your consumption of red and processed meats is advised.
- **Frequent Physical Activity:** Maintaining a healthy body weight and bolstering the immune system can be achieved by regular physical activity like at least 150 minutes of moderate to intense activity or 75 minutes of hard exercise per week.[105]

B. Occupational as well as Environmental Exposures: Minimizing exposure to these substances may help reduce the risk of blood cancer. This includes:

- **Benzene:** It's critical to reduce exposure to this chemical, which is present in some sectors and vocations. Blood cancer risk may be higher for those employed in sectors such as chemical production, rubber manufacturing, and petroleum refining. Minimizing exposure to benzene and adhering to safety procedures can be advantageous.
- **Ionizing Radiation:** The risk of blood cancer can be decreased by reducing exposure to ionizing radiation, which includes radiation therapy and excessive medical imaging tests. Observe suggested practices and talk to medical professionals about any possible risks.[106]

C. Genetic testing and counseling: Hereditary genetic mutations may occasionally be linked to blood cancer. Individuals may think about genetic counseling and testing to determine their risk and investigate preventive options if there is a family history of blood malignancy or if there are known genetic syndromes that raise the risk.[107]

It's crucial to remember that although taking these precautions may lower your chance of getting blood cancer, they cannot completely prevent it. The management and treatment of blood cancer depend heavily on routine medical examinations, early detection, and swift intervention.

8. FUTURE PERSPECTIVE:

The blood cancer review article's section on the future perspective outlines prospective paths and developments that could influence blood cancer research and clinical practice. The following topics might be covered in the section on future perspectives:

A. Precision Clinical Techniques: The management of blood cancer may benefit greatly from the application of precision medicine techniques. Next-generation sequencing and other advancements in genomic profiling can help identify particular genetic mutations, chromosomal abnormalities, and molecular signatures linked to distinct subtypes of blood cancer. By using the individual's distinct molecular profile to inform the choice of targeted therapies or immunotherapy, this information can help tailor treatment plans.[108]

B. Immunotherapies and Combination Therapies: Immune-mediated therapies have been remarkably successful in treating some blood cancers like immune checkpoint inhibitors as well as CAR-T cell therapies. Immunotherapies may be applied to a wider range of blood cancer subtypes in the future, and their efficacy may be maximized by integrating them along with targeted therapies or conventional treatment modalities. Research should be directed toward the development of strategies to overcome resistance and improve the durability of response, as well as the identification of predictive biomarkers for immunotherapy response.[109]

C. Liquid Biopsies and Early Detection: It is possible to detect minimal residual disease in blood cancer, monitor treatment response, and detect circulating tumor DNA and other biomarkers in samples of blood by developing and implementing liquid biopsies. If the disease continues, liquid biopsies can offer a non-invasive, real-time evaluation of tumor dynamics, enabling individualized treatment modifications and prompt action.[110]

D. Novel Therapeutic Targets: Additional investigation into the molecular pathways that support the pathogenesis of blood cancer may identify novel targets for treatment. Researching particular immune-related mechanisms,

epigenetic changes, and signaling pathways may result in the creation of novel targeted treatments. The safety, effectiveness, and potential synergistic effects of these novel therapeutic approaches when combined with currently available treatments should be the focus of preclinical and clinical research.[111]

E. Artificial Intelligence and Machine Learning Integration: Research on blood cancer and clinical practice could be transformed by the combination of artificial intelligence (AI) and machine learning methodologies. In order to create predictive models for prognosis, treatment response, and therapy optimization, artificial intelligence (AI) algorithms can evaluate enormous volumes of data, like genetic profiles, treatment outcomes, as well as patient characteristics. AI-powered driven decision support systems could help physicians make better treatment choices, leading to better patient outcomes and efficacy of treatment.[112]

F. Patient-centered Care and Survivorship: The significance of patient-centered care and survivorship should be emphasized in future perspectives in blood cancer research. The psychosocial and persistent impacts of blood cancer and its therapies on patients' quality of life should be better understood. The long-term results and general well-being of survivors can be greatly enhanced by putting in place comprehensive programs for survivorship that attend to their social, emotional, and physical needs.[113]

This review article can offer insights into the possible advancements and directions that can shape the field by talking about these future perspectives. It emphasizes how crucial it is to continue research, work together, and develop new technologies to improve blood cancer patients' long-term results, diagnosis, and effectiveness of treatment.

CONCLUSION

In conclusion, through this analysis of the complexities surrounding blood cancer offers a comprehensive look at the disease's complexity. Many studies have been conducted on the interactions between genetic, environmental as well as immune factors that lead to the development and spread of blood cancer. The review focuses on the various subtypes of blood cancer, each of which poses particular difficulties for diagnosis and treatment. The paper also highlights how important it is for developments in genetic and molecular research to advance our knowledge of blood cancer. A new era of personalized medicine has been brought by the identification of particular genetic mutations and molecular pathways, which have opened the door for targeted therapies. These discoveries have enormous potential to enhance treatment results and reduce adverse effects. The review also explores the opportunities and challenges related to current diagnostic techniques, emphasizing the need for more specific and sensitive methods. Because timely intervention is crucial to the successful management of blood cancer, research efforts are being directed toward developing innovative diagnostic tools. The review also highlights the impact of immunotherapy, which has evolved over time and includes treatments like immune checkpoint inhibitors as well as CAR-T cell therapy, on the field of blood cancer. Immunotherapeutic approaches, on the other hand, show great promise in using the immune system of the body to target the cancer cells, providing patients with new hope. In summary, the review highlights the need for continued research and collaboration to address the remaining challenges, even though significant advancement has been made in understanding and treating blood cancer. Because blood cancer is so complex, a multidisciplinary approach involving physicians, researchers and industry partners, is necessary to keep expanding our understanding and creating more potent treatment plans. All things considered, the thorough review is an invaluable tool for scientists and medical professionals, promoting a better comprehension of the complexities associated with blood cancer and directing future efforts toward more advanced detection and therapy.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Li Y, Fan Z, Meng Y, Liu S, Zhan H. Blood-based DNA methylation signatures in cancer: A systematic review. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2023 Jan 1;1869(1):166583.

2. Yong JH, Mai AS, Matetić A, Elbadawi A, Elgendy IY, Lopez-Fernandez T, Mamas MA. Cardiovascular Risk in Patients with Haematological Malignancies: A Systematic Review and Meta-Analysis of 1,960,144 cases. The American journal of cardiology. 2023 Dec 1.

3. Paul S, Kantarjian H, Jabbour EJ. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc 2016; 91: 1645–1666

4. Logan AC. Adult acute lymphocytic leukemia: Strategies for selection of consolidation therapy. Journal of the National Comprehensive Cancer Network. 2023 Nov 25;21(Supplement):9-12.

5. Deshmukh P, Jadhav CR. A survey of detection of Leukemia using white blood cell segmentation. Int J Trends Eng Res. 2015:294-8.

6. Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chemical Biology Letters. 2023;10(1):451-.

7. Turcotte LM, Whitton JA, Leisenring WM, Howell RM, Neglia JP, Phelan R, Oeffinger KC, Ness KK, Woods WG, Kolb EA, Robison LL. Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report. Blood, The Journal of the American Society of Hematology. 2023 Jan 5;141(1):90-101.

8. Pitel BA, Zepeda-Mendoza C, Sachs Z, Tang H, Shivaram S, Sharma N, Smadbeck JB, Smoley SA, Pearce KE, Luoma IM, Cook J. Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia. Blood cancer journal. 2023 Sep 6;13(1):138.

9. Campbell M, Kiss C, Zimmermann M, Riccheri C, Kowalczyk J, Felice MS, Kuzmanovic M, Kovacs G, Kosmidis H, Gonzalez A, Bilic E. Childhood acute lymphoblastic leukemia: results of the randomized acute lymphoblastic leukemia intercontinental-Berlin-Frankfurt-Münster 2009 trial. Journal of Clinical Oncology. 2023 Jul 1;41(19):3499-511.

10. Bielorai B, Fisher T, Waldman D, Lerenthal Y, Nissenkorn A, Tohami T, Marek D, Amariglio N, Toren A. Acute lymphoblastic leukemia in early

childhood as the presenting sign of ataxia-telangiectasia variant. Pediatric hematology and oncology. 2013 Sep 1;30(6):574-82.

11. Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC. NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network. 2021 Jan 6;19(1):16-27.

12. Shahrabi S, Maleknia M, Tavakolifar Y, Zayeri ZD, Saki N. Neutropenia and leukemia development: genetic risk factors and prognosis. Leukemia & lymphoma. 2019 Jun 19.

13. Little MP, Wakeford R, Zablotska LB, Borrego D, Griffin KT, Allodji RS, de Vathaire F, Lee C, Brenner AV, Miller JS, Campbell D. Radiation exposure and leukaemia risk among cohorts of persons exposed to low and moderate doses of external ionising radiation in childhood. British Journal of Cancer. 2023 Oct 19;129(7):1152-65.

14. Poynter JN, Richardson M, Roesler M, Blair CK, Hirsch B, Nguyen P, Cioc A, Cerhan JR, Warlick E. Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study. International journal of cancer. 2017 Jan 1;140(1):23-33.

15. Bi X, French Z, Palmisiano N, Wen KY, Wilde L. The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions. Annals of Hematology. 2022 Jun;101(6):1251-9.

16. IARC W. Global Cancer Observatory. Cancer today. Disponible en: https://gco. iarc. fr/today/data/factsheets/populations/32-argentina-fact-sheets. pdf Fecha de consulta. 2018 Oct.

17. Sehgal S, Mujtaba S, Gupta D, Aggarwal R, Marwaha RK. High incidence of Epstein Barr virus infection in childhood acute lymphocytic lukemia: A preliminary study. Indian journal of pathology and microbiology. 2010 Jan 1;53(1):63-7.

18. Curado MP, Pontes T, Guerra-Yi ME, Cancela MD. Leukemia mortality trends among children, adolescents, and young adults in Latin America. Revista Panamericana de Salud Pública. 2011 Feb;29(2):96-102.

19. Shahrabi S, Maleknia M, Tavakolifar Y, Zayeri ZD, Saki N. Neutropenia and leukemia development: genetic risk factors and prognosis. Leukemia & lymphoma. 2019 Jun 19.

20. Mahaja SH, Golait SS, Meshram A, Jichlkan N. 'Detection of types of acute leukemia. Int. J. Comput. Sci. Mobile Comput. 2014 Mar;3(3):104-11.

21. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. The American journal of medicine. 1996 May 1;100(5):555-70.

22. Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. Jama. 2014 Dec 3;312(21):2265-76.

23. Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, Pfirrmann M, International BCR-ABL Study Group. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia. 2019 May;33(5):1173-83.

24. Mendez-Hernandez A, Moturi K, Hanson V, Andritsos LA. Hairy cell leukemia: where are we in 2023?. Current Oncology Reports. 2023 Apr 25:1-8.

25. Gallegos-Arreola M, Borjas-Gutiérrez C, Zúñiga-González GM, Figuera LE, Puebla-Pérez AM, García-González JR. Pathophysiology of acute lymphoblastic leukemia. Clinical Epidemiology of Acute Lymphoblastic Leukemia-From the Molecules to the Clinic. InTech: Mexico. 2013 Apr 17:43-73.

26. Tebbi CK. Etiology of acute leukemia: A review. Cancers. 2021 May 8;13(9):2256.

27. Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer discovery. 2020 Apr 1;10(4):552-67.

28. Dander E, Palmi C, D'Amico G, Cazzaniga G. The bone marrow niche in b-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia. International Journal of Molecular Sciences. 2021 Apr 23;22(9):4426.

29. Zhou X, Medina S, Bolt AM, Zhang H, Wan G, Xu H, Lauer FT, Wang SC, Burchiel SW, Liu KJ. Inhibition of red blood cell development by arsenic-induced disruption of GATA-1. Scientific Reports. 2020 Nov 4;10(1):19055.

30. Li Z, Deng M, Huang F, Jin C, Sun S, Chen H, Liu X, He L, Sadek AH, Zhang CC. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cellular & Molecular Immunology. 2020 Mar;17(3):272-82.

31. Wang Y, Du X, Gong Y, Jiang Y, Zheng Y. Influencing factors of cancer-related fatigue in acute leukemia patients: A cross-sectional study. Heliyon. 2023 Dec 1;9(12):20-26.

32. Bryce C. Persistent night sweats: diagnostic evaluation. American Family Physician. 2020 Oct 1;102(7):427-33.

33. Ahmed A, Saeed S, Soliman DS, Haddad F, Abuasab T, Abbas F, Abdulla MA, Mohamed SF. Hematoma or Bleeding As Initial Presentation of Chronic Myeloid Leukemia (CML). Blood. 2022 Nov 15;140(Supplement 1):12231-2.

34. Cenariu D, Iluta S, Zimta AA, Petrushev B, Qian L, Dirzu N, Tomuleasa C, Bumbea H, Zaharie F. Extramedullary hematopoiesis of the liver and spleen. Journal of clinical medicine. 2021 Dec 13;10(24):5831.

35. Vogado LH, Veras RM, Araujo FH, Silva RR, Aires KR. Leukemia diagnosis in blood slides using transfer learning in CNNs and SVM for classification. Engineering Applications of Artificial Intelligence. 2018 Jun 1;72:415-22.

36. Percival ME, Lai C, Estey E, Hourigan CS. Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood reviews. 2017 Jul 1;31(4):185-92.

37. Dorfman LE, Floriani MA, Oliveira TM, Cunegatto B, Rosa RF, Zen PR. The role of cytogenetics and molecular biology in the diagnosis, treatment and monitoring of patients with chronic myeloid leukemia. Jornal Brasileiro de Patologia e Medicina Laboratorial. 2018 Mar;54:83-91.

38. Tumani H, Petereit HF, Gerritzen A, Gross CC, Huss A, Isenmann S, Jesse S, Khalil M, Lewczuk P, Lewerenz J, Leypoldt F. S1 guidelines "lumbar puncture and cerebrospinal fluid analysis"(abridged and translated version). Neurological Research and Practice. 2020 Dec;2:1-28.

39. Griffiths EA, Carraway HE, Chandhok NS, Prebet T. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. Leukemia research. 2020 Apr 1;91:106339.

40. Kery M, Papandreou I. Emerging strategies to target cancer metabolism and improve radiation therapy outcomes. The British Journal of Radiology. 2020 Nov 1;93(1115):20200067.

41. Aureli A, Marziani B, Sconocchia T, Del Principe MI, Buzzatti E, Pasqualone G, Venditti A, Sconocchia G. Immunotherapy as a turning point in the treatment of acute myeloid leukemia. Cancers. 2021 Dec 13;13(24):6246.

42. Leotta S, Condorelli A, Sciortino R, Milone GA, Bellofiore C, Garibaldi B, Schininà G, Spadaro A, Cupri A, Milone G. Prevention and treatment of acute myeloid leukemia relapse after hematopoietic stem cell transplantation: the state of the art and future perspectives. Journal of Clinical Medicine. 2022 Jan 4;11(1):253.

43. Harris MF, Knechtli C. Lymphoma. BMJ. 2014 Jun 16;348.

44. Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, Wang ML. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood advances. 2020 Jul 14;4(13):2927-38.

45. Donzel M, Bonjour M, Combes JD, Broussais F, Sesques P, Traverse-Glehen A, de Martel C. Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. Eclinicalmedicine. 2022 Dec 1;54.

46. Harbron RW, Pasqual E. Ionising radiation as a risk factor for lymphoma: A review. Journal of Radiological Protection. 2020 Nov 20;40(4):R151.

47. Shree T, Li Q, Glaser SL, Brunson A, Maecker HT, Haile RW, Levy R, Keegan TH. Impaired immune health in survivors of diffuse large B-cell lymphoma. Journal of Clinical Oncology. 2020 May 5;38(15):1664.

48. O'Donnell JS, Hunt SK, Chappell KJ. Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma. The Lancet Haematology. 2023 Jul 1;10(7):e539-48.

49. Argyrakopoulou G, Dalamaga M, Spyrou N, Kokkinos A. Gender differences in obesity-related cancers. Current obesity reports. 2021 Jun;10:100-15.

50. Weniger MA, Küppers R. Molecular biology of Hodgkin lymphoma. Leukemia. 2021 Apr;35(4):968-81.

51. Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. The Lancet. 2021 Oct 23;398(10310):1518-27.

52. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-hodgkin lymphoma. The lancet. 2017 Jul 15;390(10091):298-310.

53. Mafra A, Laversanne M, Gospodarowicz M, Klinger P, De Paula Silva N, Pineros M, Steliarova-Foucher E, Bray F, Znaor A. Global patterns of non-Hodgkin lymphoma in 2020. International Journal of Cancer. 2022 Nov 1;151(9):1474-81.

54. Kaczmarska A, Derebas J, Pinkosz M, Niedźwiecki M, Lejman M. The landscape of secondary genetic rearrangements in pediatric patients with B-cell acute lymphoblastic leukemia with t (12; 21). Cells. 2023 Jan 18;12(3):357.

55. Bou Antoun N, Chioni AM. Dysregulated signalling pathways driving anticancer drug resistance. International Journal of Molecular Sciences. 2023 Jul 30;24(15):12222.

56. Kolijn PM, Langerak AW. Immune dysregulation as a leading principle for lymphoma development in diverse immunological backgrounds. Immunology Letters. 2023 Sep 27.

57. Vom Stein AF, Hallek M, Nguyen PH. Role of the tumor microenvironment in CLL pathogenesis. InSeminars in Hematology 2023 Dec 26. WB Saunders.

58. Zhuang S, Yang Z, Cui Z, Zhang Y, Che F. Epigenetic alterations and advancement of lymphoma treatment. Annals of Hematology. 2023 Aug 15:1-20.

59. Zhang W, Peng J, Zhao S, Wu W, Yang J, Ye J, Xu S. Deep learning combined with radiomics for the classification of enlarged cervical lymph nodes. Journal of Cancer Research and Clinical Oncology. 2022 Oct;148(10):2773-80.

60. Ohta R, Nishikura N, Sano C. Peripheral T-cell Lymphoma With Acute Exacerbating Fatigue and Chest Pain: A Case Report. Cureus. 2022 Jul 28;14(7).

61. Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. American journal of hematology. 2022 Jul;97(7):951-65.

62. Liu Y, Wang Y, Wang P, Yu Q. A retrospective study to evaluate the CT and MR imaging findings of non-Hodgkin's lymphoma affecting the jaw bones. Oral Radiology. 2022 Oct;38(4):509-16.

63. Chojak R, Koźba-Gosztyła M, Polańska K, Rojek M, Chojko A, Bogacz R, Skorupa N, Więcław J, Czapiga B. Surgical resection versus biopsy in the treatment of primary central nervous system lymphoma: a systematic review and meta-analysis. Journal of Neuro-Oncology. 2022 Dec;160(3):753-61.

64. Trab T, Baech J, Jakobsen LH, Husby S, Severinsen MT, Eloranta S, Gørløv JS, Jørgensen JM, Gudbrandsdottir S, Larsen TS, Brown P. Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. The Lancet Haematology. 2023 Oct 1;10(10):e838-48.

65. Waldstein C. Radiotherapy update: current role of radiotherapy in the treatment of lymphomas. memo-Magazine of European Medical Oncology. 2023 Feb;16(1):62-6.

66. Pelcovits A, Ollila TA, Olszewski AJ. Advances in immunotherapy for the treatment of cutaneous T-cell lymphoma. Cancer Management and Research. 2023 Dec 31:989-98.

67. Smyth E, Cheah CY, Seymour JF. Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies. Cancer Treatment Reviews. 2023 Jan 5:102510.

68. Falade AS, Redd RA, Shah H, Baron K, Iyengar S, Desai SH, Ansell SM, Micallef I, Nedved A, Ganesan N, Chang T. Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents. Blood. 2023 Nov 28;142:3062.

69. Monteith BE, Sandhu I, Lee AS. Management of Multiple Myeloma: A Review for General Practitioners in Oncology. Current Oncology. 2023 Apr 22;30(5):4382-401.

70. Bal S, Giri S, Godby KN, Costa LJ. Revisiting the impact of immunoglobulin isotypes in multiple myeloma. Annals of Hematology. 2022 Apr;101(4):825-9.

71. Charliński G, Jurczyszyn A. Non-secretory multiple myeloma: Diagnosis and management. Advances in Clinical and Experimental Medicine. 2022;31(1):95-100.

72. Ganzel C, Trestman S, Levi S, Gatt ME, Lavi N, Vaxman I, Rouvio O, Magen H, Lebel E, Horowitz NA, Leiba M. Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group. Leukemia & Lymphoma. 2022 Dec 6;63(14):3448-55.

73. Duran Lozano L. Genetic predisposition for Multiple Myeloma. Identification and functional characterization of risk variants (Doctoral dissertation, Lund University).

74. Huber JH, Ji M, Shih YH, Wang M, Colditz G, Chang SH. Disentangling age, gender, and racial/ethnic disparities in multiple myeloma burden: a modeling study. Nature communications. 2023 Sep 20;14(1):5768.

75. Gonsalves WI, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Annals of internal medicine. 2022 Dec;175(12):ITC177-92.

76. Hvidtfeldt UA, Chen J, Rodopoulou S, Strak M, de Hoogh K, Andersen ZJ, Bellander T, Brandt J, Forastiere F, Brynedal B, Hertel O. Multiple myeloma risk in relation to long-term air pollution exposure-A pooled analysis of four European cohorts. Environmental Research. 2023 Dec 15;239:117230.

77. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. American journal of hematology. 2022 Aug;97(8):1086-107.

78. Zhang F, Zhuang J. Pathophysiology and therapeutic advances in myeloma bone disease. Chronic Diseases and Translational Medicine. 2022 Dec;8(4):264-70.

79. Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ, Kastritis E, Garderet L, Gozzetti A, van de Donk NW, Weisel KC. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. The Lancet Oncology. 2023 Jul 1;24(7):e293-311.

80. Seesaghur A, Petruski-Ivleva N, Banks V, Wang JR, Mattox P, Abbasi A, Maskell J, Neasham D, Ramasamy K. Bone Pain As a Presenting Symptom in Patients with Newly Diagnosed Multiple Myeloma in the Primary Care Setting: A Population-Based Cohort Study. Blood. 2020 Nov 5;136:18.

81. Aworanti OW, Ogundeji SP, Adeoye OA, Shokunbi WA. Multiple myeloma with unexplained isolated anaemia in a 24year old man-a case report. African Health Sciences. 2022 Dec 21;4(4):64-9.

82. Rana R, Cockwell P, Pinney J. Multiple Myeloma and the Kidney. InPrimer on Nephrology 2022 May 28 (pp. 843-859). Cham: Springer International Publishing.

83. Lan X, Zhang F, Yang C, Su W, Du J, Liu S, Chen M, Han B, Zhou D, Zhuang J. Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib, cyclophosphamide, and dexamethasone. Chronic Diseases and Translational Medicine. 2023.

84. Hildenbrand N, Klein A, Maier-Hein K, Wennmann M, Delorme S, Goldschmidt H, Hillengass J. Identification of focal lesion characteristics in MRI which indicate presence of corresponding osteolytic lesion in CT in patients with multiple myeloma. Bone. 2023 Oct 1;175:116857.

85. Claveau JS, Murray DL, Dispenzieri A, Kapoor P, Binder M, Buadi F, Dingli D, Fonder A, Gertz M, Gonsalves W, Hayman S. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment. Leukemia. 2023 Jan;37(1):1-4.

86. Ascione S, Harel S, Besson FL, Belkhir R, Henry J, Royer B, Arnulf B, Mariette X, Seror R. Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma. Haematologica. 2023 Nov 11;108(11):3160.

87. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J. Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center. Blood. 2023 Nov 28;142:4962.

88. Xu J, An G, Qiu L. Immunotherapy for multiple myeloma: new chances and hope. Cancer Biology & Medicine. 2023 Oct 10;20(10):695.

89. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, The Journal of the American Society of Hematology. 2009 Jul 30;114(5):937-51.

90. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H. Revised international prognostic scoring system for myelodysplastic syndromes. Blood, The Journal of the American Society of Hematology. 2012 Sep 20;120(12):2454-65.

91. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of clinical oncology. 2007 Aug 10;25(23):3503-10.

92. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2008 Sep 15;113(6):1351-61.

93. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia. 2012 Jan;26(1):101-5.

94. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood, The Journal of the American Society of Hematology. 2012 Jan 12;119(2):569-72.

95. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Kandoth C. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011 Jul;25(7):1153-8.

96. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The lancet oncology. 2009 Mar 1;10(3):223-32.

97. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, De Castro C, Ravandi F, Helmer III R. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006 Apr 15;106(8):1794-803.

98. Jaffe R. WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. 2008:358-60.

99. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014 Jul;28(7):1407-13.

100. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England Journal of Medicine. 2010 Sep 16;363(12):1117-27.

101. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S. Ruxolitinib proves superior to best available therapy in a prospective, randomized, phase 3 study (RESPONSE) in patients with polycythemia vera resistant to or intolerant of hydroxyurea. InHaematologica 2014 Jun 1 (Vol. 99, pp. 790-790). VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY: FERRATA STORTI FOUNDATION.

102. Ghafoor B, Masthan SS, Hameed M, Akhtar HH, Khalid A, Ghafoor S, Allah HM, Arshad MM, Iqbal I, Iftikhar A, Husnain M. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects. Annals of Hematology. 2023 Jul 6:1-8.

103. Cao XX, Yi SH, Jiang ZX, He JS, Yang W, Du J, Sun CY, Wu Y, Chen WM, Liu XJ, Li BZ. Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China. Leukemia & Lymphoma. 2021 Sep 19;62(11):2657-64.

104. Kapoor P, Rajkumar SV. Current approach to Waldenström macroglobulinemia. Blood Reviews. 2023 Aug 26:101129.

105. Willard VW, Bonner MJ, Guill AB. Healthy lifestyle choices after cancer treatment. Late effects of treatment for brain tumors. 2009:343-52.

106. Iwasaki M, Itoh H, Sawada N, Tsugane S. Exposure to environmental chemicals and cancer risk: epidemiological evidence from Japanese studies. Genes and Environment. 2023 Mar 22;45(1):10.

107. Singh DN, Daripelli S, Bushara MO, Polevoy GG, Prasanna M, Singh Sr DN, AlAmin M. Genetic Testing for Successive Cancer Treatment. Cureus. 2023 Dec 4;15(12).

108. Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabières C, Staaf J, Ploeger C, Lassen U, Le Tourneau C, Lehtiö J. Precision cancer medicine: Concepts, current practice, and future developments. Journal of Internal Medicine. 2023 Oct;294(4):455-81.

109. Chergui A, Reagan JL. Immunotherapy in acute leukemias: Past success paves the way for future progress. Cancers. 2023 Aug 17;15(16):4137.

110. Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, Perlow H, Baker MJ. Liquid biopsies: the future of cancer early detection. Journal of translational medicine. 2023 Feb 11;21(1):118.

111. Khadela A, Postwala H, Rana D, Dave H, Ranch K, Boddu SH. A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer. Medical Oncology. 2023 Apr 18;40(5):152.